Category: cell biology

List of retractions, corrections grows for Duke researchers

cov200hDuke researcher Michael Foster and his former co-author Erin Potts-Kant are adding to their notice count with a major correction from late last year to a paper on how certain cells in mice respond to a pneumonia infection, citing “potential discrepancies in the data.”

The correction is actually a partial retraction: The note explains that parts of three figures should be discounted.

We’ve also recently unearthed multiple corrections and two retractions from the pair that we missed from earlier in 2015.

After questions about the data in the corrected paper arose, the authors were able to replicate most of the experiments in the paper, according to the note. But since the paper was published, the senior author passed away, closing her lab, so they couldn’t repeat all of the work.

Here’s the correction notice for “Mast cell TNF receptors regulate responses to Mycoplasma pneumoniae in surfactant protein A (SP-A)−/− mice,” published in The Journal of Allergy and Clinical Immunology:

Continue reading List of retractions, corrections grows for Duke researchers

Second of 3 retractions appears for biologist, the result of “a substantial number of falsifications”

Screen Shot 2016-01-13 at 10.19.01 AMA cell biologist who falsifed Western blots has notched a second retraction, with one more expected after a investigation at Nanyang Technological University in Singapore.

First author Sudarsanareddy Lokireddy, now apparently a research fellow at Harvard, did not agree to the retraction, the result of “a substantial number of falsifications.”

In December, we covered the results of the NTU investigation, where Lokireddy used to work. During that investigation, he admitted to falsifying data, Research Integrity Officer Tony Mayer told us. The end result: three retractions.

One of those papers was retracted by Cell Metabolism in December. The second paper, published in Molecular Endocrinology, has been cited 52 times, according to Thomson Scientific’s Web of Knowledge. The retraction note explains which figures were falsified:

Continue reading Second of 3 retractions appears for biologist, the result of “a substantial number of falsifications”

IVF embryo paper pulled for plagiarism, errors, lack of permissions

6A journal is pulling an article (with approval of “most” of the authors) because a similar paper had already been published in Chinese.

That wasn’t the only problem with “Aneuploidy analysis of non-pronuclear embryos from IVF with use of array CGH: a case report,” published in the Journal of Molecular Histology. 

The retraction note lists the three things that led to the paper’s retraction:

Continue reading IVF embryo paper pulled for plagiarism, errors, lack of permissions

Four retractions follow Swedish government findings of negligence, dishonesty

242915_1uu_logoA Swedish ethical review board has censured two biologists and their employer, Uppsala University, for events related to “extensive image manipulations” in five papers published between 2010 and 2014. The case has led to criticism from an outside expert — who brought the allegations to Uppsala — over the current system in Sweden for handling such investigations.

Four of the papers have been retracted, and the authors have requested a correction in the fifth.

After an eight-month investigation, in September the government-run Expert Group for Scientific Misconduct at the Central Ethical Review Board in Stockholm, Sweden, concluded that Uppsala professor Kenneth Söderhäll — who has published more than 200 papers — and lecturer Irene Söderhäll acted “negligently” and “dishonestly” by Continue reading Four retractions follow Swedish government findings of negligence, dishonesty

Five years after a retraction, company’s stock is up more than 500%

wntloggawntresearchwebny1Is ethical behavior good for business?

Five years ago this month, Swedish pharmaceutical company WntResearch immediately notified shareholders when authors retracted a 2009 Proceedings of the National Academy of Sciences (PNAS) paper on a potential cancer therapy that was key to the company’s business.

At the time, the company’s decision to disclose the retraction hurt its finances, as WntResearch delayed its planned initial public offering for three weeks. It also offered investors and shareholders the opportunity to withdraw their shares of WntResearch stock.

But, aside from one of the paper’s co-authors, “No one did that,” Nils Brünner, WntResearch’s CEO, told us. Since the company’s IPO on December 17, 2010, its stock price has increased from Continue reading Five years after a retraction, company’s stock is up more than 500%

Stem cell researcher who sued Harvard, Brigham & Women’s is leaving his post

anversa
Piero Anversa
A stem cell researcher who sued his employers, Harvard and Brigham & Women’s Hospital, is headed to Switzerland.

Piero Anversa‘s departure follows the dismissal of his suit last summer. Anversa filed the suit with colleague Annarosa Leri, claiming that an investigation into their work damaged their reputations:

they lost a multimillion-dollar offer to purchase their company, Autologous/Progenital; and both Plaintiffs have had possible employment offers at several institutions postponed.

Anversa’s lawyer, Tracey Miner, confirmed that he was moving:

Continue reading Stem cell researcher who sued Harvard, Brigham & Women’s is leaving his post

Cholesterol paper duplicated; “The authors believed that they had taken the necessary steps to withdraw.”

Biological Reviews

A review journal is pulling a 2013 article about advances in researchers’ understanding of cholesterol after seeing the same article in another journal.

Although the retracted paper appeared first — online in Biological Reviews in February, 2013 — the journal decided to retract it after learning the authors had initially submitted it elsewhere. The first submission was eventually published (with the exception of one author) in 2014 in Frontiers in Bioscience. 

The authors say they “believed that they had taken the necessary steps to withdraw their paper from Frontiers in Bioscience before they submitted to Biological Reviews in June 2012.” Here’s more from the retraction notice:

Continue reading Cholesterol paper duplicated; “The authors believed that they had taken the necessary steps to withdraw.”

Biology journal bans plagiarizers, reviewers with non-institutional email addresses

87959_relDNA and Cell Biology has declared it will ban any authors who submit plagiarized manuscripts for three years, and will no longer accept suggestions of reviewers with non-institutional email addresses.

The move comes after a wave of hundreds of retractions stemming from fake peer reviews, often occurring when authors supply fake emails for suggested reviewers.

In an editorial published online October 23, editor Carol Shoshkes Reiss notes that the decision to ban authors who plagiarize material stems from a rash of recent submissions containing overlapping text: Continue reading Biology journal bans plagiarizers, reviewers with non-institutional email addresses

Author with three retractions objects to mega-correction following investigation

DevelopmentWe’ve uncovered a “mega-correction“ for a 2010 paper in Development, posted as the result of an investigation into the first author which has already led to three retractions.

Last year, the Utrecht University investigation into Pankaj Dhonukshe found “manipulation in some form” in four papers, and concluded that he committed a “violation of academic integrity.” The investigation also led to the retraction of a 2012 Cell paper and two papers in Nature that were co-authored by Dhonukshe. 

Development began investigating the corrected paper after being contacted by one of the authors and alerted to the results of the university’s investigation. The notice includes a statement from Dhonukshe objecting to the correction. Continue reading Author with three retractions objects to mega-correction following investigation

Dutch investigation of researcher violated rules of “fair play”: Ombudsman

Pankaj Dhonukshe
Pankaj Dhonukshe

The National Ombudsman of The Netherlands has criticized some aspects of an investigation by Utrecht University that found a researcher had committed “a violation of academic integrity.”

Specifically, the Ombudsman found the investigation — which we covered last year — did not adequately involve the affected researcher, Pankaj Dhonukshe, and therefore violated rules of “fair play.” Dhonukshe expressed relief in a statement he emailed to us about the ruling: Continue reading Dutch investigation of researcher violated rules of “fair play”: Ombudsman